Route to improving Type 1 diabetes mellitus glycaemic outcomes: real-world evidence taken from the National Diabetes Audit

AimTo use general practice-level data for England, available through the National Diabetes Audit, and primary care prescribing data to identify prescription treatment factors associated with variations in achieved glucose control (HbA(1c)). MethodsGeneral practice-level National Diabetes Audit data on Type 1 diabetes, including details of population characteristics, services, proportion of people achieving target glycaemic control [HbA(1c) 58 mmol/mol (7.5%)] and proportion of people at high glycaemic risk [HbA(1c) >86 mmol/ml (10%)], were linked to 2013-2016 primary care diabetes prescribing data on insulin types and blood glucose monitoring for all people with diabetes. ResultsA wide variation was found between the 10(th) percentile and the 90(th) percentile of general practices in both target glycaemic control (15.6% to 44.8%, respectively) and high glycaemic risk (4.8% to 28.6%, respectively). Our analysis suggests that, given the extrapolated total of 280 000 people with Type 1 diabetes in the UK, there may be the potential to increase the number of those within target glycaemic control from 80 000 to 101 000; 53% of this increase (11 000 people) would result from service improvements and 47% (10 000 people) from medication and technology changes. The same improvements would also provide the opportunity to reduce the number of people at high glycaemic risk from 42 000 to 26 500. A key factor associated with practice-level target HbA(1c) achievement would be greater use of insulin pumps for up to an additional 56 000 people. ConclusionIf the HbA(1c) achievement rates in service provision, medication and use of technology currently seen in practices in the 90(th) percentile were to be matched with regard to HbA(1c) achievement rates in all general practices, glycaemic control might be improved for 36 500 people, with all the attendant health benefits.